About Ceramide synthase 2
Ceramide synthase 2 (CERS2) is a protein
from Homo sapiens identified by UniProt accession
Q96G23, 380 residues long.
MolForge cross-references it against 0 known binders and
149 disease associations.
Target properties
| Protein name | Ceramide synthase 2 |
|---|
| UniProt accession | Q96G23 |
|---|
| Gene | CERS2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 380 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (149)
Diseases linked to this target (Open Targets).
- creatinine measurement · score 0.24
- glomerular filtration rate · score 0.23
- reticulocyte count · score 0.21
- apolipoprotein A 1 measurement · score 0.19
- high density lipoprotein cholesterol measurement · score 0.18
- HbA1c measurement · score 0.18
- cystatin C measurement · score 0.17
- mean reticulocyte volume · score 0.15
- prostate carcinoma · score 0.12
- mean platelet volume · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96G23-F1 | alphafold | PREDICTED | 86.58 | — |
Amino-acid sequence (380 residues)
MLQTLYDYFW WERLWLPVNL TWADLEDRDG RVYAKASDLY ITLPLALLFL IVRYFFELYV ATPLAALLNI KEKTRLRAPP NATLEHFYLT SGKQPKQVEV ELLSRQSGLS GRQVERWFRR RRNQDRPSLL KKFREASWRF TFYLIAFIAG MAVIVDKPWF YDMKKVWEGY PIQSTIPSQY WYYMIELSFY WSLLFSIASD VKRKDFKEQI IHHVATIILI SFSWFANYIR AGTLIMALHD SSDYLLESAK MFNYAGWKNT CNNIFIVFAI VFIITRLVIL PFWILHCTLV YPLELYPAFF GYYFFNSMMG VLQLLHIFWA YLILRMAHKF ITGKLVEDER SDREETESSE GEEAAAGGGA KSRPLANGHP ILNNNHRKND
Explore Ceramide synthase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets